$44.50
2.38[5.65%]
Last update: 2:02PM Get Real Time Here
Crinetics Pharmaceuticals
(NASDAQ:CRNX)Latest News for Crinetics Pharmaceuticals Stock (NASDAQ:CRNX)
Crinetics Pharmaceuticals Stock (NASDAQ: CRNX)
Categories: All
Thursday, March 28, 2024
Wednesday, March 20, 2024
- Oppenheimer Maintains Outperform on Crinetics Pharmaceuticals, Raises Price Target to $55Benzinga Newsdesk - Mar 20, 2024, 11:52AM
- JMP Securities Maintains Market Outperform on Crinetics Pharmaceuticals, Raises Price Target to $80Benzinga Newsdesk - Mar 20, 2024, 9:35AM
- HC Wainwright & Co. Maintains Buy on Crinetics Pharmaceuticals, Raises Price Target to $60Benzinga Newsdesk - Mar 20, 2024, 6:35AM
- JonesTrading Maintains Buy on Crinetics Pharmaceuticals, Raises Price Target to $56Benzinga Newsdesk - Mar 20, 2024, 6:08AM
Tuesday, March 19, 2024
- Crinetics Pharmaceuticals shares are trading lower after the company filed for the resale of up to 8.33 million shares by the selling stockholders.Benzinga Newsdesk - Mar 19, 2024, 4:46PM
- Crinetics Pharmaceuticals Inc Files For Resale Of Up To 8.33M Shares By The Selling StockholdersBenzinga Newsdesk - Mar 19, 2024, 4:43PM
- Endocrine Disease-Focused Crinetics Pharmaceuticals Stock Soars On Tuesday - Here's WhyVandana Singh - Mar 19, 2024, 2:48PM
- Why Peraso Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionAvi Kapoor - Mar 19, 2024, 1:48PM
- HC Wainwright & Co. Reiterates Buy on Crinetics Pharmaceuticals, Maintains $50 Price TargetBenzinga Newsdesk - Mar 19, 2024, 12:24PM
- National CineMedia Reports Upbeat Results, Joins Nordstrom, Core & Main And Other Big Stocks Moving Higher On TuesdayAvi Kapoor - Mar 19, 2024, 10:03AM
- Market-Moving News for March 19thBenzinga Newsdesk - Mar 19, 2024, 8:41AM
- Crinetics Pharmaceuticals shares are trading higher after the company's Phase 3 PATHFNDR-2 trial of paltusotine in acromegaly achieved the primary and all secondary endpoints.Benzinga Newsdesk - Mar 19, 2024, 6:19AM
- Crinetics Pharmaceuticals Announced Topline Results From PATHFNDR-2 Phase 3 Trial Of Paltusotine For Acromegaly Achieving The Primary And All Secondary Endpoints; NDA Submission To FDA Expected In 2H 2024Benzinga Newsdesk - Mar 19, 2024, 6:06AM
Wednesday, March 13, 2024
- JMP Securities Reiterates Market Outperform on Crinetics Pharmaceuticals, Maintains $60 Price TargetBenzinga Newsdesk - Mar 13, 2024, 11:25AM
- Oppenheimer Reiterates Outperform on Crinetics Pharmaceuticals, Raises Price Target to $54Benzinga Newsdesk - Mar 13, 2024, 8:34AM
- HC Wainwright & Co. Reiterates Buy on Crinetics Pharmaceuticals, Maintains $50 Price TargetBenzinga Newsdesk - Mar 13, 2024, 7:29AM
Friday, March 08, 2024
Wednesday, March 06, 2024
Monday, March 04, 2024
Friday, March 01, 2024
Thursday, February 29, 2024
- JMP Securities Maintains Market Outperform on Crinetics Pharmaceuticals, Raises Price Target to $60Benzinga Newsdesk - Feb 29, 2024, 2:19PM
- Oppenheimer Maintains Outperform on Crinetics Pharmaceuticals, Raises Price Target to $48Benzinga Newsdesk - Feb 29, 2024, 10:39AM
- The Analyst Verdict: Crinetics Pharmaceuticals In The Eyes Of 6 ExpertsBenzinga Insights - Feb 29, 2024, 8:01AM
- Baird Maintains Outperform on Crinetics Pharmaceuticals, Raises Price Target to $52Benzinga Newsdesk - Feb 29, 2024, 7:05AM
Wednesday, February 28, 2024
- Crinetics Pharmaceuticals Q4 EPS $(0.90) Misses $(0.86) EstimateBenzinga Newsdesk - Feb 28, 2024, 4:35PM
- Crinetics Pharmaceuticals: Q4 Earnings InsightsBenzinga Insights - Feb 28, 2024, 4:35PM
- Crinetics Pharmaceuticals shares are trading higher after the company announced an oversubscribed $350 million private placement.Benzinga Newsdesk - Feb 28, 2024, 8:57AM
- Crinetics Pharmaceuticals Announces Oversubscribed $350M Private Placement Of 8,333,334 Shares Of Common Stock At A Price Of $42/ShareBenzinga Newsdesk - Feb 28, 2024, 8:02AM
- Earnings Scheduled For February 28, 2024Benzinga Insights - Feb 28, 2024, 6:24AM
Tuesday, February 27, 2024
Friday, February 02, 2024
Tuesday, January 23, 2024
Tuesday, January 16, 2024
Wednesday, January 03, 2024
Thursday, December 28, 2023
Tuesday, December 19, 2023
- Endocrine Diseases-Focused Crinetics Pharmaceuticals Highlights Favorable Initial Findings From Mid-Stage StudyVandana Singh - Dec 19, 2023, 12:51PM
- Cantor Fitzgerald Reiterates Overweight on Crinetics Pharmaceuticals, Maintains $50 Price TargetBenzinga Newsdesk - Dec 19, 2023, 12:08PM
- Crinetics Pharmaceuticals shares are trading higher after the company announced initial findings from its ongoing open-label Phase 2 study of paltusotine for the treatment of acromegaly and carcinoid syndrome.Benzinga Newsdesk - Dec 19, 2023, 10:58AM
- Analyst Scoreboard: 4 Ratings For Crinetics PharmaceuticalsBenzinga Insights - Dec 19, 2023, 8:00AM
- HC Wainwright & Co. Reiterates Buy on Crinetics Pharmaceuticals, Maintains $42 Price TargetBenzinga Newsdesk - Dec 19, 2023, 7:43AM